Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 26, 2011

Biogen Idec Reports Positive Data from Second Phase III Trial with Multiple Sclerosis Drug

  • Biogen Idec reported positive topline data from a second Phase III study with its oral drug candidate BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis (RRMS). Results from the Confirm study follow less than a week after Biogen Idec reported positive results from the first Phase III BG-12 study, Define.

    The Confirm trial showed that treating RRMS patients using either twice- or thrice-daily oral BG-12 reduced the annualized relapse rate (ARR) by 44% and 51%, respectively, compared with placebo. Treatment with the comparator reference drug, subcutaneous glatiramer acetate, resulted in a 29% reduction in ARR at two years.

    BG-12 therapy in addition met all secondary relapse and MRI endpoints. “We now have strong positive results for BG-12 in two robust pivotal clinical trials with more than 2,600 patients,” remarks Doug Williams, Ph.D., Biogen Idec executive vp for R&D. “We are gratified by these strong efficacy and safety results, which, when combined with BG-12’s oral route of administration, position it as a potentially important MS therapy.” 

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »